Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
04 2021
Historique:
received: 10 04 2020
revised: 02 12 2020
accepted: 02 12 2020
pubmed: 15 12 2020
medline: 8 9 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Altered gut microbiota composition and function have been associated with inflammatory bowel diseases, including ulcerative colitis (UC), but the causality and mechanisms remain unknown. We applied 16S ribosomal RNA gene sequencing, shotgun metagenomic sequencing, in vitro functional assays, and gnotobiotic colonizations to define the microbial composition and function in fecal samples obtained from a cohort of healthy individuals at risk for inflammatory bowel diseases (pre-UC) who later developed UC (post-UC) and matched healthy control individuals (HCs). Microbiota composition of post-UC samples was different from HC and pre-UC samples; however, functional analysis showed increased fecal proteolytic and elastase activity before UC onset. Metagenomics identified more than 22,000 gene families that were significantly different between HC, pre-UC, and post-UC samples. Of these, 237 related to proteases and peptidases, suggesting a bacterial component to the pre-UC proteolytic signature. Elastase activity inversely correlated with the relative abundance of Adlercreutzia and other potentially beneficial taxa and directly correlated with known proteolytic taxa, such as Bacteroides vulgatus. High elastase activity was confirmed in Bacteroides isolates from fecal samples. The bacterial contribution and functional significance of the proteolytic signature were investigated in germ-free adult mice and in dams colonized with HC, pre-UC, or post-UC microbiota. Mice colonized with or born from pre-UC-colonized dams developed higher fecal proteolytic activity and an inflammatory immune tone compared with HC-colonized mice. We have identified increased fecal proteolytic activity that precedes the clinical diagnosis of UC and associates with gut microbiota changes. This proteolytic signature may constitute a noninvasive biomarker of inflammation to monitor at-risk populations that can be targeted therapeutically with antiproteases.

Sections du résumé

BACKGROUND & AIMS
Altered gut microbiota composition and function have been associated with inflammatory bowel diseases, including ulcerative colitis (UC), but the causality and mechanisms remain unknown.
METHODS
We applied 16S ribosomal RNA gene sequencing, shotgun metagenomic sequencing, in vitro functional assays, and gnotobiotic colonizations to define the microbial composition and function in fecal samples obtained from a cohort of healthy individuals at risk for inflammatory bowel diseases (pre-UC) who later developed UC (post-UC) and matched healthy control individuals (HCs).
RESULTS
Microbiota composition of post-UC samples was different from HC and pre-UC samples; however, functional analysis showed increased fecal proteolytic and elastase activity before UC onset. Metagenomics identified more than 22,000 gene families that were significantly different between HC, pre-UC, and post-UC samples. Of these, 237 related to proteases and peptidases, suggesting a bacterial component to the pre-UC proteolytic signature. Elastase activity inversely correlated with the relative abundance of Adlercreutzia and other potentially beneficial taxa and directly correlated with known proteolytic taxa, such as Bacteroides vulgatus. High elastase activity was confirmed in Bacteroides isolates from fecal samples. The bacterial contribution and functional significance of the proteolytic signature were investigated in germ-free adult mice and in dams colonized with HC, pre-UC, or post-UC microbiota. Mice colonized with or born from pre-UC-colonized dams developed higher fecal proteolytic activity and an inflammatory immune tone compared with HC-colonized mice.
CONCLUSIONS
We have identified increased fecal proteolytic activity that precedes the clinical diagnosis of UC and associates with gut microbiota changes. This proteolytic signature may constitute a noninvasive biomarker of inflammation to monitor at-risk populations that can be targeted therapeutically with antiproteases.

Identifiants

pubmed: 33310084
pii: S0016-5085(20)35533-5
doi: 10.1053/j.gastro.2020.12.004
pii:
doi:

Substances chimiques

Bacterial Proteins 0
Biomarkers 0
Protease Inhibitors 0
Peptide Hydrolases EC 3.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1532-1545

Subventions

Organisme : CIHR
ID : 143253
Pays : Canada
Organisme : CIHR
ID : 1715-000-001
Pays : Canada

Investigateurs

Paul Beck (P)
Charles Bernstein (C)
Kenneth Croitoru (K)
Leo Dieleman (L)
Brian Feagan (B)
Anne Griffiths (A)
David Guttman (D)
Kevan Jacobson (K)
Gilaad Kaplan (G)
Denis O Krause (DO)
Karen Madsen (K)
John Marshall (J)
Paul Moayyedi (P)
Mark Ropeleski (M)
Ernest Seidman (E)
Mark Silverberg (M)
Scott Snapper (S)
Andy Stadnyk (A)
Hillary Steinhart (H)
Michael Surette (M)
Dan Turner (D)
Thomas Walters (T)
Bruce Vallance (B)
Guy Aumais (G)
Alain Bitton (A)
Maria Cino (M)
Jeff Critch (J)
Lee Denson (L)
Colette Deslandres (C)
Wael El-Matary (W)
Hans Herfarth (H)
Peter Higgins (P)
Hien Huynh (H)
Jeff Hyams (J)
David Mack (D)
Jerry McGrath (J)
Anthony Otley (A)
Remo Panancionne (R)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Heather J Galipeau (HJ)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Alberto Caminero (A)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Williams Turpin (W)

Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Miriam Bermudez-Brito (M)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Alba Santiago (A)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Josie Libertucci (J)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Marco Constante (M)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Juan Antonio Raygoza Garay (JA)

Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Gaston Rueda (G)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Sarah Armstrong (S)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Alex Clarizio (A)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Michelle I Smith (MI)

Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

Michael G Surette (MG)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Premysl Bercik (P)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Kenneth Croitoru (K)

Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: Ken.Croitoru@sinaihealth.ca.

Elena F Verdu (EF)

Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada. Electronic address: verdue@mcmaster.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH